DivestmentAug 4, 2026, 04:38 PM
Pacira BioSciences Divests iovera® Business for Up to $140M
AI Summary
Pacira BioSciences, Inc. reported Q2 2026 financial results, showing a return to profitability with net income of $4.7 million, compared to a net loss in the prior year. Total revenues increased by 6.2% to $192.4 million. The company also completed the divestment of its iovera® cryoanalgesia business to Zimmer, Inc. for up to $140.0 million, including an upfront payment of $70.0 million.
Key Highlights
- Divested iovera® cryoanalgesia business to Zimmer, Inc. for up to $140.0M.
- Reported Q2 2026 net income of $4.7M, up from a $4.8M net loss in Q2 2025.
- Total revenues for Q2 2026 increased 6.2% to $192.4M.
- Basic and diluted EPS for Q2 2026 was $0.12, compared to $(0.11) in Q2 2025.
- Cash and cash equivalents increased to $205.9M as of June 30, 2026.
- Net cash provided by operating activities for YTD 2026 was $83.1M.
- Purchased $50.4M in treasury stock during the first six months of 2026.
Price Impact
More from PCRX